Colorectal Cancer

A genetic counselor discussed the various hereditary breast and ovarian cancer syndrome-associated cancers among men and how to manage them at the FORCE Annual Meeting.

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Getting a third opinion probably didn't save my life, but it definitely bought me more time.

Tumor testing can lead to different treatment choices and better outcomes.

As a parent facing cancer, we just want to know that our children will emerge on the other side of our diagnosis and be alright.

The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor Braftovi (encorafenib), the MEK inhibitor Mektovi (binimetinib), and the EGFR inhibitor Erbitux (cetuximab) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC) following one or two prior lines of treatment in the metastatic setting.

Scientists have spent 35 years seeking ways to disable RAS, a gene that’s mutated in many cancer types. Now, they’re moving closer to solutions.

The FDA approved Opdivo plus Yervoy to treat a certain subset of patients with metastatic colorectal cancer.

The American Cancer Society issued an updated guideline recommendation that now calls for screening to begin at age 45 for individuals at average risk for colorectal cancer.

Understanding one’s biomarkers, such as microsatellite stable (MSS) or instable (MSI) status in tumors, is key in understanding how a patient with colorectal cancer may be treated.

Take a look at the top five CURE stories of June 2018 in this video.

Recent research found that patients under 50 were less likely to have a treatment-determining biomarker than their older counterparts.

This year’s survey is expanded to better learn about the experience of caregivers, with a selection of questions specifically for them. The Alliance asks that just one caregiver per patient fill out the survey.

Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

The FDA approved the Paxman Scalp Cooling System for patients with solid tumors who wish to prevent chemotherapy-related hair loss.

By getting their tumor genetically tested, a patient may find out that they are eligible for certain treatment options.

It was the drop heard 'round the colorectal cancer world.

After losing her husband and sister to cancer, journalist Katie Couric became an advocate for collaborative efforts to improve prevention and treatment.

The science behind immunotherapy and gastrointestinal cancers is not quite perfected yet, but one subset of patients is seeing remarkable results.

Despite improved outcomes, the researchers also found that side effects with checkpoint inhibition often affected the dermatologic, gastrointestinal, pulmonary, renal, endocrine and hepatic systems in patients.

CURE spoke with a childhood development specialist and colorectal cancer survivor to offer firsthand advice and tips on how to discuss a cancer diagnosis with children of any age.

Survivors of colorectal cancer have a greater chance of hypertension (high blood pressure) and worse blood pressure control compared with people who do not have cancer, according to study findings.

The National Colorectal Cancer Roundtable has created a special toolkit to help physicians successfully determine and evaluate family history to detect colorectal cancer at an earlier age.

“Young people, in general, think they are invincible. I certainly did.” Said Stacy Hurt, an early-age onset rectal cancer survivor.

If patients with colon cancer follow the previously-issued American Cancer Society guidelines on nutrition and physical activity, they can improve outcomes in to survivorship.

With immunotherapy continuing to command headlines in the world of oncology, it’s no surprise that patients with a variety of cancers wonder whether the strategy might help them address and overcome their illnesses.

Funded posthumously by a "Jeopardy!" winner, an immunotherapy research project is under way.

The combination induced a 31 percent disease control rate (DCR) in patients with heavily-pretreated metastatic colorectal cancer (mCRC).

The understanding of genetic mutations, like tumors that are microsatellite instability-high (MSI-H), and the therapies that go along with them is transforming the world of colorectal cancer, according to John Marshall, M.D.